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Abstract
Post-Traumatic Stress Disorder (PTSD) is a stress-based condition that a person develops after
being exposed to an overwhelmingly traumatic event. Military troops frequently experience
stress and trauma, making them highly susceptible to psychopathology. This paper evaluates nine
clinical trials that used either magic mushrooms, marijuana, or MDMA as an adjunct to
traditional psychotherapy to treat veterans who suffer from anxiety, depression, PTSD,
suicidality, and other psychopathologies. Multiple scholarly journals and articles were read and
analyzed, which show support for the therapeutic potential of psychedelic drugs in treating
veterans with PTSD. After receiving psychedelic-assisted psychotherapy, the research showed
participants experienced a multitude of positive effects, including an improved ability to access
and process traumatic memories, a renewed sense of motivation and enthusiasm to engage in life,
as well as an increased sense of empathy for self and others. Additionally, psychedelic drugs
have been shown to reduce physical pain as well as symptoms of anxiety, depression, PTSD, and
suicidality. The studies support the use of psychedelic drugs as an adjunct to psychotherapy and
show promise in treating other mental health and wellness issues.

Keywords: Post-Traumatic Stress Disorder (PTSD), Magic Mushrooms, Psilocybin, Psilocin,
Psychedelic Drugs, Psychedelic-Assisted Psychotherapy, Marijuana, 3, 4Methylenedioxymethamphetamine, MDMA, Ecstasy, Veterans
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Therapeutic Potential of Psychedelic Drugs, Specifically Magic Mushrooms, Marijuana,
and MDMA with Veterans Who Suffer from Post-Traumatic Stress Disorder (PTSD)
Therapeutic potentials of psychedelic drugs, specifically magic mushrooms, marijuana,
and 3, 4-methylenedioxymethamphetamine (MDMA) in the treatment of veterans who suffer
from anxiety, depression, Post-Traumatic Stress Disorder (PTSD), and suicidality are no
hallucination. Military training and service are very dangerous. Soldiers are called upon to
manage natural disasters, control rioters, and fight wars. As a result, service members are
repeatedly exposed to highly stressful situations where traumatic events are likely to occur.
Veterans’ negative experiences accumulate and their trauma compounds, manifesting as anxiety,
depression, PTSD, and suicidality. Without proper treatment, veterans will continue to suffer in
multiple life domains across their lifespan.
To better understand and treat mental illnesses, the Food and Drug Administration (FDA)
and Drug Enforcement Agency (DEA) have allowed researchers to focus their attention on the
therapeutic potentials of psychedelic drugs, including magic mushrooms, marijuana, and
MDMA. Research on these medications have shown them to be highly effective in treating a
wide range of psychopathologies (Doblin, 2002; Amoroso, 2015; Sessa et al., 2019; Krediet et
al., 2020). As a result, the FDA designated magic mushrooms as a “breakthrough treatment” for
treatment resistant depression (TRD), and MDMA as a “breakthrough treatment” for PTSD
(Krediet et al., 2020). The goal of psychedelic-assisted psychotherapy is to help veterans process,
integrate, and recover from their trauma using medications known to facilitate transformative
experiences. Receiving psychedelic drugs during a therapy session typically causes a person to
experience hallucinations as well as changes in sensation and perception, commonly referred to
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as “tripping”. Although psychedelic trips change the treatment experience; “tripping” is not
required to achieve profound and long-lasting psychological benefits.
By summarizing multiple studies, this paper serves to inform psychotherapists,
physicians, and other mental health providers about the therapeutic potentials of psychedelic
drugs and the positive effects experienced by those who consumed the medications. Scientific
research indicates psychedelic drugs are effective in treating psychopathology and possess
tremendous therapeutic potential for veterans who suffer from anxiety, depression, PTSD, and
suicidality.
Literature Review
Post-traumatic stress is a normal human response to traumatic events, whereas PostTraumatic Stress Disorder (PTSD) is a more serious condition that impacts the anatomy and
physiology of the brain (Brenner et al., 2009; How PTSD Affects The Brain, 2017). The
American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) describes PTSD as a condition that develops after a person becomes exposed to a
stressful or traumatic event such as the threat of death, serious injury, or sexual violence (DSM5, 2013). “The onset of PTSD is influenced by a complex interaction of biological, cognitive,
and psychosocial factors across multiple time points” (Forbes et al., 2019, p. 97). The severity of
a person’s psychological distress following a traumatic event is often impacted by several
factors, including their age, and gender, the type of trauma they experienced, previous traumatic
experiences, their culture, and other protective factors (Jackson-Cherry et al., 2014).
The DSM-5 categorizes PTSD symptoms into four domains: intrusion, negative
alterations, reactivity, and avoidance (DSM-5, 2013). Intrusive images, thoughts, and memories
are common experiences among PTSD sufferers (DSM-5, 2013). Overwhelming sensory
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intrusions that cause veterans to feel as though they are reliving their traumatic experience are
known as flashbacks or dissociative episodes (Morgan, 2020). Negative alterations are associated
with persistent and exaggerated pessimistic beliefs or expectations about oneself and the world,
distorted cognitions about the cause or consequence of the trauma, and the inability to experience
positive emotions (DSM-5, 2013). Arousal and reactivity are physiologically linked and typically
manifest as hypervigilance, irritability, reckless or self-destructive behavior, outbursts, sleep
disturbances, and issues with concentration (DSM-5, 2013). Finally, avoidance is a hallmark
symptom of PTSD and serves as a protective factor, which helps veterans disconnect from their
painful or traumatic experiences mentally, physically, and emotionally (Morgan, 2020).
Veterans who experience trauma often suffer in silence, making the statistical prevalence
difficult to calculate. According to the Department of Veterans Affairs (DVA) during their
lifetime, half of all U.S. adults will experience at least one traumatic event, 15 million Americans
will suffer from PTSD annually, and six percent of the U.S. population will develop some form
of PTSD (How Common is PTSD in Adults?, 2020a, para. 7). “PTSD is a growing health concern
associated with increased occupational, relationship, and other psychological dysfunction, as
well as a decreased quality of life, and enhanced risk of suicide” (Barone et al., 2019, p. 200).
The aforementioned statistics are alarming and indicate the need for well-trained, highly skilled,
trauma informed, psychotherapists who use empirically validated and cost-effective methods to
help service members with anxiety, depression, PTSD, and suicidality; work through their
negative experiences; manage their triggers and reduce symptoms; as well as heal and grow in
response to treatment.
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Post-Traumatic Stress Disorder (PTSD) in Veterans
In addition to protecting and serving their country, people join the military for a variety
of reasons including adventure, family tradition, career opportunities, the GI Bill, and skills
development (Applegate et al, 1990). Newly enlisted soldiers are often sent off to boot camp
unprepared for the physical, mental, and emotional challenges that lie ahead (Lowe et al., 2012).
The military system is designed to break down a soldier and push them to their limits, to rebuild
them into a highly-skilled, physically-fit, fighting machine (Applegate et al., 1990). Military
training and service is serious, as are the risks. Every soldier sacrifices something of themselves
while in the service and some make the ultimate sacrifice: their lives. The Congressional
Research Service (CRS) reported that between 2006 and 2021, 18,571 active-duty personnel lost
their lives while serving in the military (Aftergood, 2021; Congressional Research Service,
2021). Military service is dangerous, as evidenced by the number of soldiers who died in the line
of duty and the number of soldiers who survived and continue to suffer.
Military service comes with unique challenges. Life as a soldier is difficult due to family
separation, frequent base changes, multiple deployments, and unpredictable hours (Burrell et al.,
2006). Soldiers can experience trauma at home and abroad as well as during peacetime, training,
and war. The tolls that the constant stress and danger have on a person are tremendous (Weitz,
2015). Active-duty military personnel, especially those who are deployed, are most effected by
high levels of anxiety, stress, and extreme pressure (Lowe et al., 2012). War and other types of
combat are physically and psychologically taxing, causing negative effects in multiple life
domains (Burrell et al., 2006). Soldiers often experience physical injuries, psychological damage,
and other forms of trauma that affect physiological functioning, mental cognition, and emotional
well-being (Lowe et al., 2012). Although the military provides mental health services, access to
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therapists and counselors is limited (Defense Health Board Task Force on Mental Health, 2007).
Therefore, soldiers who need help working through trauma related to military life do not receive
the support they need. Even fewer mental health providers are on the front lines in combat zones,
trauma hospitals, or other dangerous locations, precisely where help is needed most (Defense
Health Board Task Force on Mental Health, 2007). Without access to therapists, veterans’
symptoms will likely increase, causing greater dysregulation across their life span.
The military idealizes physical toughness and mental fortitude (Applegate et al., 1990),
which promotes a culture of masculinity (Weitz, 2015). Masculinist cultures pressure members
to remain silent about traumatic events, thus exacerbating the accumulative effects on their
overall health and well-being (Weitz, 2015). As a result, veterans’ symptoms are downplayed,
rationalized, or ignored, leading to an increase in dysfunction across multiple life domains
(Jackson-Cherry et al., 2014). Untreated trauma has been shown to increase veterans’ rates of
anxiety, depression, PTSD, suicidality, and other psychopathologies (Burrell et al., 2006).
Additionally, certain types of trauma, such as combat and rape, are known to produce higher
rates of PTSD in veterans (Jackson-Cherry et al., 2014). Military service members face danger
on and off the battlefield, which exponentially increases their chances of developing a mental
health disorder.
Investigations into PTSD have helped researchers understand the severity of the
condition and identify ways in which the disorder negatively impacts soldiers’ lives. “PTSD is
one of the most common and costly disorders in veterans” (Congressional Budget Office, 2012,
p. 3; Forbes et al., 2019). According to the he Department of Veterans Affairs (DVA),
approximately 12% of soldiers deployed in Desert Storm and between 11- 20% of soldiers
deployed during operations Iraqi Freedom and Enduring Freedom were diagnosed with PTSD
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(How Common is PTSD in Veterans?, 2020b). Of the veterans who served in the Vietnam War,
30% experienced PTSD during their lifetime (How Common is PTSD in Veterans?, 2020b). The
impact of PTSD can be seen throughout history, further confirming the effects of war related
trauma.
Military stress and trauma have profound effects on veterans’ mental health and
wellbeing, often causing chaos and dysfunction in multiple life domains. A study conducted in
2009 by Greenberg and associates provides evidence that mental health problems, especially
PTSD, are risk factors for imprisonment among male veterans (Greenberg et al., 2009). Women
and minorities are known to experience disproportionately high rates of PTSD (Jackson-Cherry
et al., 2014). Service women are forced to function in a culture of misogyny and encounter both
combat trauma and military sexual trauma (MST), which includes harassment, sexual assault,
and rape (Weitz, 2015). Studies conducted by the DVA state 23% of women experienced a
sexual assault while serving in the military (How Common is PTSD in Veterans?, 2020b). As
women’s roles in the military increase, so does their exposure to combat situations, war, and
MST, which increase their probability of developing PTSD (Reisman, 2016). Minorities continue
to face multiple challenges while serving in the military, including racial discrimination,
culturism, and the like. One study found that two-thirds of minorities on active duty reported
experiencing offensive racial behaviors in the last year, and one in 10 reported career-related
racial discrimination (Antecol et al., 2009). The negative impacts that trauma has on veterans can
be seen across gender and race.
PTSD is an economic burden that plagues veterans, their families, society, and the health
care system. Treating Afghanistan and Iraq veterans with PTSD costs the DVA more than two
billion dollars annually, or approximately $8,300 per person (Congressional Budget Office,
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2012; Reisman, 2016). The cost to treat veterans with PTSD is three and a half times higher than
costs for those without the disorder (Congressional Budget Office, 2012; Reisman, 2016).
Studies conducted by the Center for Military Health Policy Research report less than half of
returning veterans who needed mental health services received treatment, and of those receiving
treatment for PTSD and major depression, less than one-third received empirically-validated care
(Tanielian et al., 2008). These statistics emphasize the need for well-trained, highly skilled,
trauma-informed psychotherapists who use scientifically validated methods to help veterans
process their traumatic experiences.
Non-PTSD Brains vs PTSD Brains
To understand PTSD, one must first understand the anatomy and physiology of the
human brain. Understanding the human brain will provide insight into the complex differences
between brains of individuals without PTSD and brains of individuals with PTSD. Three brain
regions are largely responsible for the formation of a person’s experiences and memories: the
amygdala, prefrontal cortex (PFC), and the hippocampus.
The amygdala is a primitive, animalistic part of the brain wired to ensure survival (How
PTSD Affects The Brain, 2017). The amygdala functions as an alarm system, and when triggered,
sends signals to the brain and body, and produces a fear response (Roozendaal et al., 2009).
When the amygdala is overactive, a person cannot think rationally because the fight or flight
response is on high alert and focused on survival (Janak et al., 2015).
The PFC is the part of the brain where decisions and thoughts are worked through, which
allows a person to regulate their emotional responses that are triggered by the amygdala
(McEwen et al., 2013; How PTSD Affects The Brain, 2017). In service members with PTSD, the
PFC cannot always complete its mission of calming down the amygdala and deescalating the
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situation (How PTSD Affects The Brain, 2017). An overactive amygdala combined with an
underactive PFC can create chaos. The co-dysfunction of the two systems causes individuals
with PTSD to feel anxious around anything related to the original trauma, have strong physical
reactions to situations that should not provoke a fear response, and avoid situations that might
trigger intense emotions and reactions (Janak et al., 2015; How PTSD Affects The Brain, 2017).
The hippocampus is the brain’s memory system and encodes experiences onto its hard
drive. After a trauma occurs, the hippocampus works to remember the event accurately while
also helping to make sense of the experience (Belleau et al, 2019; How PTSD Affects The Brain,
2017). Trauma is typically overwhelming and much of the information does not get processed,
encoded, or integrated correctly (McEwen et al., 2013). Because veterans’ brains and bodies are
in a constant state of miscommunication, they have difficulty reconciling traumatic events as
well as consolidating and integrating their experiences and memories.
No two PTSD sufferers experience the exact same trauma, symptoms, or brain changes;
however, there are patterns that can be identified and evaluated (How PTSD Affects The Brain,
2017). Research shows that the brain of a person with PTSD looks and functions very differently
than a non-PTSD brain. Critical brain structures including the amygdala, anterior circulate cortex
(ACC), PFC, and the hippocampus are impacted by stress and trauma (Franz et al., 2020).
Research into how PTSD effects the brain has discovered that changes occur in many regions:
“Studies have shown that chronic stress is associated with structural brain changes, including
spine density, dendritic length, and branching neurons in multiple brain regions” (Franz et al.,
2020, p. 1210). Dahlgren and others further contend that “Neuroimaging studies have
consistently shown a decrease in the activation of the medial prefrontal cortex (mPFC), including
the anterior cingulate cortex (ACC), and the medial frontal gyrus (mFG) in individuals with
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PTSD” (Dahlgren et al., 2018, p. 1133). PTSD brains are associated with smaller brain volume in
multiple regions, smaller hippocampal volume (Franz et al., 2020), and show indications of PFC
dysfunction (Arnsten, 2015). These brain changes impact everything from biochemistry to
sensations and perceptions to thoughts and feelings, to physical and psychological responses
(Janak et al, 2015). PTSD causes changes in veterans’ brains, which manifest as anxiety,
depression, and suicidality.
Over the past 50 years, innovative methods of neuroimaging have enabled scientists to
identify “mechanisms in the brain that cause mental disorders as well as understand changes in
functional brain circuitry that underline PTSD” (Bremner, 2007, p. 394; How PTSD Affects The
Brain, 2017). These new scanning techniques include magnetic resonance imaging (MRI),
functional magnetic resonance imaging (fMRI), positron emission tomography (PET), and
single-photon emission computerized tomography (SPECT). Each of these scanning technologies
have unique abilities and applications that are used to identify dysfunctional regions and systems
within the brain. “An MRI uses a powerful magnet to throw the electrons that make up the brain
tissue out of their normal patterns and measures the time it takes for them to return to their
normal resting state” (Bremner, 2007, p. 400). fMRI is used to examine, measure, and map the
brain’s functional anatomy as well as track metabolism in the brain that demonstrates regional,
time-varying changes (Glover, 2011). PET uses radiolabeled drugs to gauge brain functions
including blood flow and oxygen consumption, measure responses to specific stimuli and track
neurotransmitters such as dopamine in different parts of the brain (Berger, 2003). SPECT uses a
gamma camera and radiolabeled tracers to gather information about blood flow and volume,
metabolism, and functional brain changes as a result of PTSD, traumatic brain injuries, and other
disease processes (Raji et al., 2014).
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Brains of PTSD sufferers are damaged and when an event occurs that sparks anxiety,
fear, or stress, it becomes difficult for their body’s collective systems to differentiate real,
perceived, and imagined threats (Reisman, 2016). The disconnection between perceptions,
thoughts, feelings, experiences, and memories cause veterans to develop psychopathologies.
Drug Classification
Psychedelics, also known as serotoninergic hallucinogens, is a broad drug category with
mechanistically dissimilar psychoactive agents (Siegel et al., 2021). Psychedelics effect brain
changes in a multitude of ways: “Psychedelics dramatically alter the user’s perceptions of their
surroundings and thoughts to create a world in which reason takes a back seat to the intensified
sensations generated by illusions, delusions, and hallucinations” (Inaba et al., 2014, p. 6.1).
Magic mushrooms, marijuana, and MDMA, also known as ecstasy, are all classified as
psychedelic drugs due to their profound effects, resulting in a mystical-spiritual experience
(Begola et al., 2018).
The Controlled Substances Act of 1970 regulates substances under federal law and places
them into one of five categories known as Schedules. Drugs are scheduled based on a
substance’s medical use, potential for abuse, and safety profile (Controlled Substance Schedules,
2021; Drug Scheduling, n.d.). Magic mushrooms, marijuana, and MDMA are all considered
psychedelics, classified as Schedule I drugs, and are, therefore, illegal at the federal level. Efforts
are currently underway to reschedule these drugs based on the overwhelming empirical evidence
that supports their overall use (Iserson, 2019). Additionally, several states have already or are in
the process of decriminalizing and/or legalizing the medical and recreational use of magic
mushrooms, marijuana, and MDMA. Decriminalization indicates a person will not be arrested or
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imprisoned if they are in possession of a small amount of a drug, whereas legalization indicates
the removal of all legal prohibitions and consequences (Drug Scheduling, n.d.).
Magic Mushrooms
Psychedelic plants and fungi grow in many regions of the world including Asia, Europe,
Mexico, and the United States (Warf, 2014). Botanical records show entheogenic plants and
fungi, such as magic mushrooms, have existed for over 250 million years (Inaba et al., 2014).
Archaeological records show early hunter gatherers consumed mushrooms as a source of food as
far back as 10,000 years (O’Regan et al., 2016). Several hundred species of mushrooms contain
psilocybin and psilocin, psychoactive substances that, when consumed, alter a person’s
perceptions. Each mushroom species has properties, potencies, and effects that make them
unique.
As humans evolved and transitioned from small tribes of hunter gatherers to living in
larger communities, they shared vital skills and knowledge such as farming, flint mapping,
smelting, firing pottery, and the use of natural medicines (Tuttle, 2014). As cultures and religions
developed, mushrooms took on more complex roles in society, serving critical ceremonial,
recreational, religious, spiritual, and medicinal functions (Guzmán, 2008). Mushroom cults
began to appear in Mesoamerica around 3000 B.C. and left artifacts such as mushroom shaped
rocks as evidence of their worship (Carod-Artal, 2015). Mushrooms containing psilocybin and
psilocin are experienced by humans as “magical” because they produce effects that are reported
as enlightening, transcending, and transformative: “Psychedelic effects include visceral
sensations, changes in sight, hearing, taste, and touch” (Inaba et al., 2014, p. 6.11), which
produce altered states of consciousness.
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Indigenous people knew which species of mushrooms produced magical experiences
centuries before modern science discovered psilocybin and psilocin. The intoxicating mindaltering effects were the reasons native peoples including the Nahuatls, Puebla, and Matlazincs,
used mushrooms in their ceremonies and rituals (Guzmán, 2008). Similarly, the Aztecs referred
to magic mushrooms as “Teonanacatl” or “Flesh of the Gods” because their consumption was
required before an individual could enter the spirit world (Carod-Artal, 2015). Psychoactive
inebriants are still being used by traditional healers and shaman around the world to tell the
future, treat illnesses, dispel curses, cast out spirits, and communicate with the gods (Guzmán,
2008).
In 1956, the primary psychedelic agents that produce the “mystical-magical” effects in
mushrooms were identified as psilocybin and psilocin. “The psychedelic effects are caused by
disrupting the neurotransmitters serotonin and dopamine as well as generating a sudden release
of norepinephrine, a stimulatory neurotransmitter that intensifies sensory perceptions (Inaba et
al., 2014, p. 6.11). In 1957, Life Magazine published an article by Gordon Wasson titled
“Seeking the Magic Mushroom,” which catalyzed people’s interest in consuming the fungi to
experience its mystical- spiritual effects (Inaba et al., 2014). Recreational use of magic
mushrooms quickly became popular and, in the 1960s, became associated with hippie culture. It
must be noted that doctors, psychotherapists, counselors, and others experimented with what
became commonly known as “shrooms” and believed the fungi had tremendous therapeutic
potential for a wide range of mental health conditions (Iserson, 2019).
In 1970, the U.S. government declared mushrooms containing psilocybin and psilocin
would be classified as a Schedule I drug (Comprehensive Drug Abuse Prevention and Control
Act, 1970). The federal government enacted laws that made it illegal to possess and consume
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“shrooms” and imposed harsh penalties on those who broke the law (Iserson, 2019). As a result,
mushroom use was pushed underground, which added fuel to the fire of people’s desire to
consume this magical drug for its mystical effects. Scientific inquiry and research with
“shrooms” became tightly controlled and only possible with special permission from the Drug
Enforcement Agency (DEA) (Iserson, 2019). Due to governmental restrictions, research on
psychedelic mushrooms and their effects were slow (Iserson, 2019). As knowledge accumulated,
researchers began to focus their efforts on the drug’s therapeutic potential in the treatment of
anxiety, depression, tobacco use, alcohol addiction, obsessive compulsive disorder (OCD), and
PTSD (Krediet et al., 2020).
According to research, subjects who participated in psilocybin-assisted psychotherapy
experienced a multiplicity of positive effects including intensified feelings of existential and
spiritual wellbeing (Ross et al., 2016). A study conducted by Mason and colleagues found that
psilocybin successfully reduced participants’ symptoms of anxiety and depression (Mason et al.,
2019). The study went on to discover that psilocybin improved creative thinking, increased
empathy levels, and enhanced participants’ well-being (Mason et al., 2019). Results from a third
study show higher doses of psilocybin resulted in improved clinical outcomes compared to lower
doses, and at a six-month follow-up, approximately 80% of participants continued to experience
significant decreases in depressed mood and anxiety (Griffiths et al., 2016). Additionally, the
study indicates that subjects developed a deeper understanding of the meaning of life,
experienced an increase in optimism, and their quality of life improved (Griffiths et al., 2016).
According to Hendricks and associates (2015), individuals who have consumed magic
mushrooms at least once in their lifetimes show significantly lower levels of psychological
distress and suicidal thinking. Research has shown that psilocybin effected a larger reduction in
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suicidal ideation than other psychedelic drugs, suggesting its therapeutic potential as a “suicide
prophylaxis” (Hendricks et al, 2015). While the true explanation for why or how it happens may
still be unresolved, there is enough evidence to suggest these medicines should be studied further
and applied to other medical and psychological conditions.
Research results strongly indicate that magic mushrooms provide substantial therapeutic
relief for individuals who suffer from mental health conditions. In fact, the amount of scientific
evidence was so strong and compelling that, in 2018, the FDA designated psilocybin a
breakthrough therapy for treatment-resistant depression (TRD). “The FDA grants this
designation for treatments that (1) are intended alone or in combination with one or more other
drugs to treat a serious or life-threatening disease or condition; and (2) preliminary clinical
evidence demonstrate substantial improvement over existing therapies” (Phase 3 Trial Program:
MDMA-Assisted Therapy for PTSD, n.d.). Research into the therapeutic potential of magic
mushrooms as a method of treating PTSD and other psychological conditions in veterans is
ongoing.
Marijuana
Cannabis sativa, also known as marijuana, grows in many parts of the world, including
the U.S. and Mexico (Warf, 2014). Marijuana’s country of origin is unknown; some experts
believe it is indigenous to temperate areas in western and central Asia, while others suggest
China or Siberia (Warf, 2014). Botanical science claims, “Cannabis has been transported widely,
providing extensive opportunities for establishment outside of its original range” (Schultes,
1981, p. 770; Small, 2015). The genus cannabis includes several species and subspecies, each
with properties, potencies, and effects that make them unique. The two most recognizable
cannabis subspecies are Cannabis sativa L. and Cannabis sativa.
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Cannabis sativa L., also known as industrial hemp, produces a fibrous material that can
be processed to make clothes, canvas, shoes, paper, and oil. Hemp’s strength and versatility
made it so valuable that its worth cannot be calculated. Hemp made it possible for sailors to
navigate the open sea by allowing them to harness the wind in their sails, clothed them on their
journeys, and provided paper for sea and star charts as well as treasure maps (Skoglund et al.,
2013; Small, 2015). Cannabis sativa L. contains 0.3% or less of Δ9-tetrahydrocannabinol (THC)
and has almost no psychoactive properties and therefore is not used as an intoxicant (Hurgobin et
al., 2021).
Conversely, Cannabis sativa, also known as marijuana, does have psychoactive properties
and is considered both a medicine and an inebriant. According to Warf, the female plant
produces a sticky resin-like substance that is rich in cannabinoids, specifically THC and
cannabidiol (CBD) (Warf, 2014). Cannabis sativa plants and products that contain 0.3% or more
of THC and used for their medicinal or intoxicating effects, are considered drug-type (Hurgobin
et al., 2021). Archaeological and written records demonstrate that for centuries, humans around
the world have exploited cannabis for cultural, medicinal, recreational, religious, and spiritual
reasons (Carod-Artal, 2015). “Due to its versality, a relationship between Cannabis and Homo
Sapiens have existed for at least 10,000 years” (Inaba et al., 2014, p. 6.26). Industrial hemp and
marijuana are woven into the world’s sociocultural fabric, uniting humanity through the drugs’
domestication, trade, and use.
As adventurers explored the world, they brought seeds of culture, religion, and cannabis
in their backpacks, sowing them along the way. Cannabis, an old-world drug, arrived in the New
World and Latin America in the early sixteenth century (Warf, 2014). Smoking cannabis for its
psychedelic effects was influenced by multiple sources and developed over time. Historical
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records show Pygmies from Uganda in East Africa smoked marijuana out of gourds going back
hundreds of years, with its use spreading amongst tribes (Inaba et al., 2014). Asian immigrants,
African slaves, and Middle Eastern peoples likely introduced the tradition of consuming or
smoking marijuana for its medicinal and psychedelic effects to the European and Western worlds
(Chasteen, 2016). Contact with the New World’s indigenous tribes introduced the practice of
smoking tobacco out of pipes (Inaba et al., 2014). Once immigrants, slaves, and other ethnic
peoples began to use indigenous pipes to smoke marijuana for its psychoactive effects, its use
spread like wildfire, even amongst Europeans (Warf, 2014).
In 1937, the U.S. passed the Marihuana Tax Act, which set up strict regulations on
cannabis and outlawed it on a national level (Pacula et al., 2017). If one was caught in possession
of cannabis, harsh punitive measures were imposed, including large fines, arrest, and
incarceration (Iserson, 2019). In 1964, two Israeli biochemists discovered marijuana’s main
psychoactive ingredient known as THC (Inaba et al., 2014). In 1970, Attorney General John
Mitchell lobbied for marijuana to be scheduled, and shortly thereafter, it became a Schedule I
drug alongside heroin, LSD, magic mushrooms, and MDMA, also known as ecstasy (Iserson,
2019). This classification hindered scientific inquiry and research into the therapeutic potential
of cannabis. Over time, however, the DEA granted scientists permission to study the effects of
cannabis on individuals who suffered from anxiety, depression, PTSD, and physical pain (Pacula
et al., 2017).
Medical research has identified two types of cannabinoid receptors, CB1 and CB2, that
are located throughout the human body. CB1 receptors are found primarily in the brain and
spinal cord, while CB2 receptors are found in the peripheral tissues, such as the stomach and
legs. Both types of CB receptors are involved in the regulation of pain, mood, appetite, sleep,
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memory, and emotional state (Iversen, 2003). Smoking or consuming marijuana products allows
THC and CBD molecules to bind with matching endocannabinoid receptors in the body and
brain to reduce anxiety, alleviate pain, and alter a person’s sensations and perceptions (Iversen,
2003).
Multiple studies have investigated the therapeutic effectiveness of Cannabis sativa for
treating PTSD. Results from one study indicated medical cannabis was an effective treatment
option for military and other service veterans with PTSD, particularly those for whom
conventional psychotherapy and psychopharmacology was ineffective (Smith et al., 2017). The
study went on to discover cannabis use results in improvements across all PTSD measures
including social, family, and pain management (Smith et al., 2017). Finally, client improvements
were associated with a 50% reduction in the use of other PTSD related medications (Smith et al.,
2017). Results from a second study found that patients reported significant symptom
improvement and increased quality of life after four months of cannabis use (Chan et al., 2017).
A third study’s results showed all PTSD symptoms including intrusions, flashbacks, irritability,
and anxiety were reduced by 50% immediately after using cannabis (LaFrance et al., 2020).
Finally, the study found the longer the research participants used cannabis, the greater their
symptoms were reduced and that higher doses of cannabis predicted larger reductions in
intrusions and anxiety than lower doses (LaFrance et al., 2020).
Additional findings indicated that “cannabinoids reduce responses to conditioned fear
cues, impair retrieval of emotionally adverse memories, and promote the extinction of fear
memories” (LaFrance et al., 2020). These research findings are significant and support the use of
cannabis as an effective treatment for veterans who suffer from symptoms of anxiety, depression,
PTSD, pain, and suicidality.
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3, 4-Methylenedioxymethamphetamine (MDMA)
In 1914, Merk, a German pharmaceutical company, discovered 3,4methylenedioxymethamphetamine (MDMA), a short acting psychostimulant with effects that last
approximately four to six hours. “MDMA’s primary mechanism of action is on the 5-HT
transporter, which results in excessive serotonin in the synaptic cleft and also interacts with other
neurotransmitters’ systems including dopamine and norepinephrine” (Amoroso, 2015, p. 339).
Research has shown that “MDMA significantly increases blood plasma levels of oxytocin, and
the subjective pro-social feelings are positively correlated to the oxytocin levels in the blood”
(Amoroso, 2015, p. 9; Dumont et al., 2009, p. 360). Commonly known as ecstasy, MDMA alters
a person’s sensory perceptions by elevating and intensifying one’s physical, mental, and
emotional senses, which promotes feelings of happiness and well-being (Inaba et al., 2014).
MDMA “operates on emotions more so than cognitive processing” (Doblin, 2002, p. 190), which
allows an individual to connect with and explore their inner thoughts and emotions. Veterans
who can process their traumatic experiences can therefore heal and achieve post-traumatic
growth in response to treatment.
During the 1950s, the U.S. became interested in psychological warfare. To study these
techniques, the military gave soldiers ecstasy to brainwash them and to understand the drug’s
overall effects (Inaba et al., 2014). The military’s experimentation was halted because of the
drug’s inability to achieve the desired results. In 1988, the DEA decided that MDMA had no
therapeutic use and classified it as a Schedule I drug, alongside heroin, LSD, magic mushrooms,
and marijuana (Controlled Substance Schedules, 2021; Drug Scheduling, n.d.; Comprehensive
Drug Abuse Prevention and Control Act, 1970). Professionals who utilized MDMA as an adjunct
to traditional psychotherapy were forced to discontinue its use or face harsh consequences

THERAPEUTIC POTENTIAL OF PSYCHODELIC DRUGS

23

including loss of license and imprisonment (Iserson, 2019). When the DEA eventually granted
researchers permission to study MDMA, research focused almost exclusively on negative aspects
of consumption, rather than its therapeutic potential (Begola et al., 2018). Once researchers were
allowed to experiment with and investigate MDMA, the therapeutic potential became clear.
The first randomized clinical trial that used MDMA-assisted psychotherapy to address
treatment resistant PTSD was published in 2010. Participants’ PTSD symptoms were assessed
using the Clinician Administered PTSD Symptoms Scale (CAPS-IV). Clients received
traditional psychotherapy and two sessions where either a placebo or 125 mg of MDMA were
administered (Mithoefer et al., 2011). The results showed that 83% of the patients who received
MDMA-assisted psychotherapy and were reassessed using the CAPS-IV no longer met the
criteria for PTSD (Mithoefer et al., 2011). Additionally, results showed that MDMA-assisted
psychotherapy clients continued to produce positive results, including decreased levels of anxiety
and depression three and a half years after their initial course of treatment (Mithoefer et al.,
2018).
In a second study, veterans with treatment resistant PTSD described qualitative
improvements in self-awareness, relationships, social skills, openness to therapy, and a reduction
in problematic substance use after being treated with MDMA (Barone et al., 2019). Participants
expressed an improved ability to process traumatic memories, experienced an increased sense of
empathy for self and others, and felt a renewed sense of motivation and enthusiasm to engage in
life (Barone et al., 2019). Barone further contends, “All research participants reported
experiencing lasting personal benefits and enhanced quality of life that extended beyond
quantifiable symptom reduction” (Barone et al., 2019, p. 199). Factors identified as being critical
to the success of MDMA-assisted psychotherapy include a strong therapeutic alliance,
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preparatory sessions, which helps prepare veterans for the experience, and integrative sessions,
which helps veterans process their experiences (Barone et al., 2019). “MDMA’s
psychopharmacological characteristics are what make it well suited as an adjunct to traumafocused psychotherapy” (Siegel et al., 2021, p. 78).
MDMA-assisted psychotherapy is delivered over a short period, is cost effective, and has
been empirically validated as effective in treating PTSD (Doblin, 2002). “Multiple studies have
shown as few as two MDMA-assisted psychotherapy sessions can successfully reduce symptoms
in patients with treatment resistant PTSD with retained remission for up to six years post
treatment” (Sessa et al., 2019, p. 138). Clinical studies investigating MDMA indicate the
medication is safe and effective in treating psychopathology (Dos Santos et al., 2018). According
to Doblin (2002), “MDMA is superior to all other psychedelics because the primary effects are
short acting which allows one to return to baseline quickly, rarely interferes with cognitive
functioning, and reduces fear and defensiveness” (p. 186). Sessa further contends, “The unique
and powerful role of psychedelic drugs is tailor-made for disorders based around anxiety and
fear, especially OCD and PTSD” (Sessa, 2014, p. 59).
In 2017, the Food and Drug Administration (FDA) designated MDMA as a breakthrough
therapy for the treatment of PTSD. Currently, phase three clinical trials are underway, which
means MDMA could be FDA approved for the treatment of veterans with PTSD as soon as
2023. Research into the therapeutic potential of MDMA as a method of treating other
psychopathologies in veterans is ongoing.
Treatment Barriers
Military veterans with anxiety, depression, PTSD, and suicidality face multiple obstacles
in accessing mental health services. In 2014, the Veterans Administration conducted an audit and
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found the greatest barrier veterans have to obtaining treatment for mental health issues was
provider availability (DVA, 2014). The lack of providers exacerbates the severity and duration of
veterans’ symptoms. Prolonged psychological pain and suffering are known to increase suicide
rates and other psychopathologies, especially among veterans (Reisman, 2016). According to the
DVA, between 18 and 22 veterans die from suicide every day (DVA, 2014), and in 2016,
veterans accounted for 20% of all suicides in the U.S. (Reisman, 2016).
Another significant barrier hindering veterans are the sociocultural stigmas associated
with mental illness and treatment. The military’s masculinist culture idealizes obedience,
physical toughness, and mental fortitude, and deviation from this norm is met with resistance
(Weitz, 2015). Research has indicated that veterans perceive mental illness as a weakness and
therefore often feel ashamed or embarrassed to seek help (Institute of Medicine (US) Committee
on the Initial Assessment of Readjustment Needs of Military Personnel, Veterans, and Their
Families, 2010; Rae Olmsted et al., 2011). As a result of the military culture and social stigmas,
veterans with anxiety, depression, PTSD, and suicidality often ignore, marginalize, or rationalize
their symptoms (Weitz, 2015). Symptom suppression increases pain and suffering, making
veterans’ mental health conditions worse, which further increases stigmas (Rae Olmsted et al.,
2011). This process demonstrates the harmful cycle stigmas, PTSD, and other psychopathologies
have on a veteran.
Stigmas extend to medication use. Rather than being inconvenienced or embarrassed by
taking FDA-approved medications such as Zoloft or Paxil, veterans often self-medicate with
alcohol and drugs (McFarling et al., 2011). Self-medicating has been shown to exacerbate
presenting symptoms, which makes treating underlying anxiety, stress, and trauma more
challenging (Jackson-Cherry et al., 2014). Medications have the potential to help many veterans
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recover; however, drugs such as Zoloft require time to reach their therapeutic potential and are
known to produce negative side effects, including cardiovascular issues, sleeping problems,
diarrhea, muscle pain, and sexual dysfunction (American Psychological Association, 2017). The
stigma surrounding the medical application of psychedelic substances to treat anxiety,
depression, PTSD, suicidality, and other psychopathology is even more pronounced than those
associated with traditional medications such as Zoloft and Paxil (McFarling et al., 2011).
Biases, stigmas, and misconceptions about mental illness, psychotherapy, medications, and
psychedelic drugs are harmful because they prevent veterans from receiving the help they need.
Clinical Mental Health Program Applications
The therapeutic potential of magic mushrooms, marijuana, and MDMA is supported by
empirical evidence that indicates psychedelics are highly effective in treating psychopathology
and reducing symptoms of anxiety, depression, PTSD, and suicidality. Psychedelic drugs are
relatively safe to consume and function as a catalyst in treating mental illness in veterans as well
as disorders resistant to traditional psychotherapeutic interventions.
A major therapeutic benefit of psychedelic drugs includes helping veterans process their
pain and trauma and allowing them to perceive the world in new ways. Psychedelics facilitate the
healing process by enhancing emotional sensitivity and promoting emotional release, which
facilitates higher levels of self-awareness. After the psychedelic effects wear off, veterans are
better able to reintegrate negative experiences and develop new ways of understanding
themselves and the world around them. Studies have found that hallucinogenic experiences were
rated among the most meaningful and spiritually significant events in a person’s life and can
improve one’s well-being and life satisfaction for up to a year after the experience (Majić et al.,
2015; Begola et al., 2018). The synergistic effects of psychedelic-assisted psychotherapy can
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help veterans heal, grow, and express a more integrated sense of themselves in response to their
traumatic experiences.
Magic mushrooms, marijuana, and MDMA will soon become FDA-approved
medications intended to be used as adjuncts to traditional psychotherapy with individuals who
suffer from anxiety, depression, PTSD, and suicidality. Psychedelic drugs and evidence-based,
trauma-informed psychotherapy are powerful tools that can help veterans reduce their
psychological pain and suffering as well as promote mental, physical, and emotional health and
wellness through transformative experiences. Regardless of a person’s intentions to utilize magic
mushrooms, marijuana, or MDMA in therapy, industry best practices require therapists to
familiarize themselves with the use of psychedelic drugs to treat psychopathologies as a method
of enriching the therapeutic alliance, supporting and facilitating clients’ healing processes, and
stimulating post-traumatic growth.
Therapists who treat veterans have common goals for their clients including improved
functionality, healing, safety, sustained recovery, wellness, and an enhanced quality of life.
Utilizing psychedelic psychotherapy has the potential to help veterans connect with traumatic
experiences, assist in the expression of thoughts and feelings, and allow them to process and
integrate memories. Research has shown that psychedelic drugs are therapeutically valid,
relatively safe to consume, cost effective, have a low potential for abuse, and reduces traditional
medication consumption by half. Most importantly, psychedelic drugs facilitate profound lifeenhancing experiences that can help veterans heal from their trauma and, therefore, can live
happier, healthier, and more functional lives.
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Discussion
Military life is marked by chaos and uncertainty. Military service is a very dangerous
occupation, with no room for error. One misstep can cost a soldier their life or the lives of fellow
troops. Anxiety, pressure, stress, and trauma build up over time and have profound effects on the
human brain, changing it in a multitude of ways. Brains of PTSD sufferers are damaged, and
when an event occurs that sparks anxiety, fear, or stress, it becomes difficult for the body’s
collective systems to differentiate real, perceived, and imagined threats (Reisman, 2016). The
disconnection between perceptions and reality, thoughts and feelings, and current experiences
and memories produce psychopathology and cause dysregulation to manifest in multiple life
domains across a soldier’s lifespan.
Troops who survive the traumas of combat and war are highly susceptible to developing
psychopathology including anxiety, depression, PTSD, and suicidality (Reisman, 2016). Soldiers
should not return home from war to suffer in silence or die by suicide, yet many do. Veterans
who suffer from PTSD face multiple treatment barriers including the inability to access mental
health providers who use evidence-based techniques; the military’s masculinist culture; stigmas
related to mental health issues, psychotherapy, traditional medications, and non-traditional drugs
such as magic mushrooms, marijuana, and MDMA. Biases, stigmas, and misconceptions
surrounding the use of psychedelic drugs persist, stifling scientific inquiry into their therapeutic
potentials and use with veterans who suffer from mental illness. Psychotherapists who treat
veterans will soon have access to powerful tools that can be used to help fight anxiety,
depression, PTSD, and suicidality.
Research into the therapeutic potential of psychedelic drugs as a method of treating
veterans with PTSD shows exceptionally promising results. Individuals who participated in
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psilocybin-assisted psychotherapy experienced a multiplicity of positive effects, including
intensified feelings of existential and spiritual well-being (Ross et al., 2016), reduced symptoms
of anxiety and depression, improved creative thinking, increased empathy levels, and enhanced
feelings of well-being (Mason et al., 2019). Additionally, subjects developed a deeper
understanding of the meaning of life and experienced both an increase in optimism and an
improvement in their quality of life (Griffiths et al., 2016).
Research participants who used medical cannabis experienced a reduction in symptoms
related to physical and psychological pain, anxiety, depression, PTSD, and suicidality (Iversen,
2003). Marijuana was also found to be effective in veterans with PTSD, particularly those for
whom conventional psychotherapy and psychopharmacology was ineffective (Smith et al.,
2017). Cannabis use resulted in improvements across all PTSD measures including social,
family, pain, and quality of life (Smith et al., 2017). These improvements were associated with a
reduction in PTSD symptoms, including intrusions, flashbacks, irritability, and anxiety
(LaFrance et al., 2020). Finally, THC and CBD have been shown to reduce responses to
conditioned fear cues, impair retrieval of emotionally adverse memories, and promote the
extinction of fear memories (LaFrance et al., 2020).
Individuals who participated in MDMA-assisted psychotherapy experienced positive
results, including decreased levels of anxiety, depression, and PTSD symptoms three and a half
years after their initial course of treatment (Mithoefer et al., 2018). Participants also described
improvements in their self-awareness, relationships, social skills; an openness to therapy; and a
reduction in problematic substance use (Barone et al., 2019). Additionally, the group of
participants who received MDMA-assisted psychotherapy expressed an improved ability to
process traumatic memories, an increased sense of empathy for themselves, and a renewed sense
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of motivation and enthusiasm to engage in life (Barone et al., 2019). Mental health providers
must recognize the therapeutic potential that exists with psychedelic-assisted psychotherapy and
be prepared to facilitate veterans’ healing and post-traumatic growth through the application of
psychedelic drugs.
Psychedelic psychotherapy may be useful for individuals who suffer from conditions
such as body dysmorphic disorder (BDD) or personality disorders (PD). Psychedelic medications
have the potential to help people with these conditions better understand themselves, their
actions, and the world from an alternative perspective. The ability for a person to suspend or
displace their perception of reality may help those who suffer from BDD or PD gain insight into
their thought processes and behavior patterns, allowing them to function more effectively in the
world.
Typically, people who suffer from mental health conditions such as anxiety, depression,
PTSD, and suicidality are prescribed medications to help manage their symptoms. In the U.S.
drugs used to treat mental illness are intended for long term use, often have side effects, and can
be expensive even with insurance. Magic mushrooms, marijuana, and MDMA are safe to
consume, effective in as few as two doses, and produce positive long-term effects. Psychedelicassisted psychotherapy can lessen the economic burden on veterans, society, and the healthcare
system by decreasing the number of medications and sessions needed to address their concerns.
The money saved utilizing psychedelic psychotherapy can be recycled back into the veteran
healthcare system to train and hire additional psychedelic psychotherapists to treat service
members with PTSD and other psychopathologies.
Despite the wealth of scientific data showing support for psychedelic-assisted
psychotherapy, limitations exist, including government restrictions, inaccurate Schedule
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placement, and legal issues. Government restrictions make it difficult for scientists to investigate
the therapeutic potentials of psychedelic drug and, therefore, limit the number of studies being
conducted. Results from approved studies found that magic mushrooms, marijuana, and MDMA
are highly effective at treating a wide range of conditions. Steps towards rescheduling these
medications have been made; however, progress is slow. Factors such as misconceptions about
psychedelic drugs, limited access to education and training, and legal consequences reduce
mental health providers’ willingness to become certified psychedelic psychotherapists.
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